|
| |
 |
|
| CORRIGENDUM |
|
| Year : 2022 | Volume
: 5
| Issue : 3 | Page : 110-111 |
|
Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study
| Date of Web Publication | 13-Oct-2022 |
Correspondence Address:
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/glioma.glioma_19_22
How to cite this article:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:110-1 |
How to cite this URL:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma [serial online] 2022 [cited 2023 Oct 2];5:110-1. Available from: http://www.jglioma.com/text.asp?2022/5/3/110/358551 |
In the article titled “Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study,” published on pages 29-38, Issue 1, Volume 5 of Glioma,[1] [Figure 1] has been incorrectly published. The correct [Figure 1] is given below.
The authors apologize for any inconvenience this correction may cause for readers and editors of Glioma.
| References | |  |
| 1. | Lin F, Guo C, Yang Q, Chen Y, Ke C, Sai K, et al. Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:29-38.  [Full text] |
[Figure 1]
|
